The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study

Not Applicable

Recruiting

• Conditions: Complement Abnormality; Peripheral Blood Mononuclear Cells; Covid19
• Interventions: Other: Blood analysis

• Registration Number: NCT05258643
• Lead Sponsor: Universitair Ziekenhuis Brussel

Brief Summary

The current study is an open, non-randomized, monocentric, and interventional study. CoViD-19 patients will be recruited at UZ Brussel after informed consent is obtained. Whole blood and serum samples will be collected during acute disease (inclusion and 7 days after inclusion) and during patient follow-up at 2 months after infection.

Sample storage and subsequent use in fundamental research will be performed at VUB Neuro-Aging and Viro-Immunotherapy.

Additionally, medical records of UZ Brussel will be searched and epidemiological, clinical, radiological, and biological data of the selected patients will be obtained at the diagnosis time point and during follow-up.

Healthy volunteers will be recruited as well in the current study, as a comparison arm, after informed consent is obtained.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-09-01
• Status Verified: 2021-04
• Study First Submitted: 2021-11-03
• Study First Submitted QC: 2022-02-25
• Last Update Submitted: 2022-02-25
• Study First Posted: 2022-02-28
• Last Update Posted: 2022-02-28
• Primary Completion: 2024-05-01
• Study Completion: 2024-09-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Positive nasopharyngeal reverse transcriptase-polymerase chain reaction for SARS-Coronavirus-02
• Signed inform consent

Healthy Volunteers

Inclusion Criteria:

• Signed inform consent

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Controle	Blood analysis	Whole blood and serum samples will be collected during the same period
Covid-19 patients	Blood analysis	Whole blood and serum samples will be collected during acute disease (inclusion and 7 days after inclusion) and during patient follow-up at 2 months after infection

Primary Outcome Measures

Name	Time	Method
Difference in complements or peripheral blood mononuclear cells between CoViD-19 patients and controls	up to 1 year

Trial Locations

Locations (1)

UZ Brussel; 🇧🇪 Jette, Brussels, Belgium